Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Viemed Healthcare (VMD) over the last 8 years, with Q3 2025 value amounting to -$968000.0.

  • Viemed Healthcare's Change in Receivables fell 796666.67% to -$968000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 11682.31%. This contributed to the annual value of $6.1 million for FY2024, which is 47400.76% up from last year.
  • Viemed Healthcare's Change in Receivables amounted to -$968000.0 in Q3 2025, which was down 796666.67% from -$240000.0 recorded in Q2 2025.
  • Viemed Healthcare's Change in Receivables' 5-year high stood at $6.0 million during Q1 2024, with a 5-year trough of -$2.8 million in Q2 2022.
  • For the 5-year period, Viemed Healthcare's Change in Receivables averaged around $931684.2, with its median value being $525000.0 (2023).
  • As far as peak fluctuations go, Viemed Healthcare's Change in Receivables surged by 59863.95% in 2024, and later plummeted by 796666.67% in 2025.
  • Viemed Healthcare's Change in Receivables (Quarter) stood at $1.8 million in 2021, then crashed by 77.6% to $397000.0 in 2022, then surged by 32.24% to $525000.0 in 2023, then crashed by 507.62% to -$2.1 million in 2024, then soared by 54.77% to -$968000.0 in 2025.
  • Its last three reported values are -$968000.0 in Q3 2025, -$240000.0 for Q2 2025, and $1.9 million during Q1 2025.